Ulisse Biomed Spa
MIL:UBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ulisse Biomed Spa
Total Equity
Ulisse Biomed Spa
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ulisse Biomed Spa
MIL:UBM
|
Total Equity
€23.7m
|
CAGR 3-Years
48%
|
CAGR 5-Years
104%
|
CAGR 10-Years
N/A
|
|
|
Genenta Science SPA
NASDAQ:GNTA
|
Total Equity
€12.5m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Philogen SpA
MIL:PHIL
|
Total Equity
€138.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Ulisse Biomed Spa
Glance View
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
See Also
What is Ulisse Biomed Spa's Total Equity?
Total Equity
23.7m
EUR
Based on the financial report for Dec 31, 2024, Ulisse Biomed Spa's Total Equity amounts to 23.7m EUR.
What is Ulisse Biomed Spa's Total Equity growth rate?
Total Equity CAGR 5Y
104%
Over the last year, the Total Equity growth was -13%. The average annual Total Equity growth rates for Ulisse Biomed Spa have been 48% over the past three years , 104% over the past five years .
